Search ACTG publications from 1/1/2006 to current.


Filter results by

Found 688 results
Found 688 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  


Smith D, Moini N, Pesano R, et al. "Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection." Clin. Infect. Dis.. 2007;44(3):456-8.
Smith DM, Mathews WChristophe. "Physicians' attitudes toward homosexuality and HIV: survey of a California Medical Society- revisited (PATHH-II)." J Homosex. 2007;52(3-4):1-9.
Smurzynski M, Collier AC, Koletar SL, et al. "AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics." HIV Clin Trials. 2008;9(4):269-82.
Smurzynski M, Wu K, Benson CA, Bosch RJ, Collier AC, Koletar SL. "Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study." J. Acquir. Immune Defic. Syndr.. 2010;55(1):117-27.
Smurzynski M, Wu K, Letendre S, et al. "Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort." AIDS. 2011;25(3):357-65.
Smurzynski M, Wu K, Schouten JT, et al. "Factors associated with remaining on initial randomized efavirenz-containing regimens." AIDS. 2013;27(12):1887-97.
Snoeck J, Kantor R, Shafer RW, et al. "Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent." Antimicrob. Agents Chemother.. 2006;50(2):694-701.
Stapleton JT, Bennett K, Bosch RJ, Polgreen PM, Swindells S. "Effect of antiretroviral therapy and hepatitis c co-infection on changes in lipid levels in HIV-Infected patients 48 weeks after initiation of therapy." HIV Clin Trials. 2007;8(6):429-36.
Stapleton JT, Chaloner K, Zhang J, et al. "GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy." AIDS. 2009;23(5):605-10.
Stein JH, Brown TT, Ribaudo HJ, et al. "Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection." AIDS. 2013;27(6):929-37.
Stein JH, Komarow L, Cotter BR, et al. "Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy." J Clin Lipidol. 2008;2(6):464-471.
Stein JH, Ribaudo HJ, Hodis HN, et al. "A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness." AIDS. 2015;29(14):1775-83.
Sterling TR, M Villarino E, Borisov AS, et al. "Three months of rifapentine and isoniazid for latent tuberculosis infection." N. Engl. J. Med.. 2011;365(23):2155-66.
Sterling TR, Scott NA, Miro JM, et al. "Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons." AIDS. 2016;30(10):1607-15.
Stewart P, Cachafeiro A, Napravnik S, et al. "Performance characteristics of the Cavidi ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay." J. Clin. Virol.. 2010;49(3):198-204.
Stone ND, Dunaway SB, Flexner C, et al. "Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects." Antimicrob. Agents Chemother.. 2007;51(7):2351-8.
Stüve O, Marra CM, Bar-Or A, et al. "Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis." Arch. Neurol.. 2006;63(10):1383-7.
Stüve O, Marra CM, Jerome KR, et al. "Immune surveillance in multiple sclerosis patients treated with natalizumab." Ann. Neurol.. 2006;59(5):743-7.
Su Z, Gulick RM, Krambrink A, et al. "Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211." J. Infect. Dis.. 2009;200(11):1724-8.
Sugarman J, Seils DM, J Watson-Ormond K, Weinfurt KP. "Using Cognitive Interviews to Enhance Measurement in Empirical Bioethics: Developing a Measure of the Preventive Misconception in Biomedical HIV Prevention Trials." AJOB Empir Bioeth. 2016;7(1):17-23.
Sulkowski MS, Kang M, Matining R, et al. "Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study." J. Infect. Dis.. 2014;209(5):658-67.
Sun J, Nagaraj HN, Reynolds NR. "Discrete stochastic models for compliance analysis based on an AIDS Clinical Trial Group (ACTG) study." Biom J. 2007;49(5):731-41.
Svensson EM, Aweeka F, Park J-G, Marzan F, Dooley KE, Karlsson MO. "Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis." Antimicrob. Agents Chemother.. 2013;57(6):2780-7.
Swindells S, Jiang H, A Mukherjee L, Winters M, Bosch RJ, Katzenstein D. "Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis." HIV Clin Trials. 2011;12(2):79-88.
Swindells S, A DiRienzo G, Wilkin T, et al. "Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression." JAMA. 2006;296(7):806-14.
Swindells S, Komarow L, Tripathy S, et al. "Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group Protocol A5253." Int. J. Tuberc. Lung Dis.. 2013;17(4):532-9.